Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel dose schedule in advanced breast cancer
NCT04192331Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Feb 2019
- Primary completion
- Jan 2023
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nab-paclitaxel in breast cancer, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression-Free Survival at 100 months. Status: unknown.
02
Drugs
nab-paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04192331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04192331.